<DOC>
	<DOCNO>NCT02539368</DOCNO>
	<brief_summary>This post-marketing observational study patient Inflammatory Bowel Disease ( specifically , Crohn 's disease Ulcerative Colitis ) prescribe Inflectra ( infliximab ) Remicade ( infliximab ) treatment . Inflectra biosimilar medicine Remicade , mean biologic medicine contains active substance Remicade ( infliximab ) . The key study objective follow : - To characterize population drug utilization pattern patient treat Inflectra Crohn 's Disease ( CD ) Ulcerative Colitis ( UC ) context standard care Remicade - To assess safety Inflectra 2-year follow-up period treatment patient CD UC context standard care Remicade - To assess effectiveness Inflectra treatment patient CD UC context standard care Remicade - To evaluate immunogenicity profile Inflectra treatment patient CD UC - To evaluate patient-reported outcome ( PRO ) include quality life ( QoL ) , work productivity healthcare resource utilization ( HRU ) patient treat Inflectra CD UC</brief_summary>
	<brief_title>Post-Marketing Use Of Inflectra ( Infliximab ) For Standard Of Care Treatment Of Inflammatory Bowel Disease</brief_title>
	<detailed_description>The study conduct accord good clinical practice ( GCP ) guideline data source validate . The source data consist hospital medical record monitor organize regular basis . Data study enter web base electronic data capture ( EDC ) system enrolment approximately every 3 month thereafter 2 year . Adverse event encode accord MedDRA 17.1 later . The sample size 3300 patient recruit 2 year . No inferential analysis plan . Statistical analysis descriptive nature .</detailed_description>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . At least 12 year age time initial confirm diagnosis CD UC least 18 year age time enrolment study . 2 . Patients prescribed Inflectra Remicade treatment CD UC prescribe accord correspond summary product characteristic ( SmPC ) determine Investigator . Patients stomas surgery/pouch include . 1 . Any report contraindication Inflectra Remicade , accord SmPC . 2 . Known hypersensitivity ( include severe , acute infusion reaction ) infliximab , excipients murine protein , time enrolment . 3 . Prior history failure respond Remicade Inflectra .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>Observational</keyword>
	<keyword>Follow-up</keyword>
	<keyword>Safety</keyword>
	<keyword>Effectiveness</keyword>
</DOC>